Ropsacitinib
As of the edition of 20 October 2026, Ropsacitinib is a small molecule: stopped in 2023; acts on TYK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 6, 1 stopped early
- Disease areas
- Skin and connective tissue; Digestive system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Ropsacitinib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TYK2 | Non-receptor tyrosine-protein kinase TYK2 | P29597 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2017 to now |